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Abstract
Background: Agaricus blazei Murill (AbM) is an edible Brazilian mushroom that has been used in
traditional medicine for a range of diseases. It has been shown to have anti-infection and anti-tumor
properties in the mouse, which are due to induction of Th1 responses. On the other hand, IgE-
mediated allergy is induced by a Th2 response.
Objective: Since according to the Th1/Th2 paradigm an increased Th1 response may promote a
reduced Th2 response, the aim was to examine whether AbM had anti-allergy effects.
Methods: A mouse model for allergy was employed, in which the mice were immunized s.c. with
the model allergen ovalbumin (OVA). Additionally, the animals were given a mushroom extract,
AndoSan™, mainly (82%) containing AbM, but also Hericium erinaceum (15%) and Grifola frondosa
(3%), or PBS p.o. either a day before or 19 days after the immunization. The mice were sacrificed
on day 26, and anti-OVA IgE (Th2 response) and IgG2a (Th1 response) antibodies were examined
in serum and Th1, Th2 and Treg cytokines in spleen cells cultures.
Results: It was found that the AndoSan™ extract both when given either before or after OVA
immunization reduced the levels of anti-OVA IgE, but not IgG2a, in the mice. There was a tendency
to reduced Th2 relative to Th1 cytokine levels in the AndoSan™ groups.
Conclusion: This particular AbM extract may both prevent allergy development and be used as a
therapeutical substance against established allergy.
Background
Agaricus blazei Murill (AbM) of the family Basidiomycetes is
a popular edible medicinal mushroom, originally native
to a small village, Piedade, in the highland areas of Atlan-
tic forest near São Paulo, Brazil. It has traditionally been
used for the prevention of a range of diseases, including
cancer, hepatitis, atherosclerosis, hypercholesterolemia,
diabetes and dermatitis [1,2]. Because of its alleged health
effects, the mushroom was brought to Japan in the mid-
60-ies and subjected to biomedical research. AbM was
found to be rich in immuno-modulating substances such
as β-glucans [3,4] and proteoglycans [5], and it had anti-
infection [6,7] and anti-tumor [4,5] effects in mice.
Anti-tumor and anti-infection immunity are both due to
Th1 responses, which also do promote autoimmune dis-
ease when overshooting. On the other hand, anti-
helminth and anti-rejection immunity are due to Th2
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responses, which may also induce IgE-mediated allergy,
whereas delayed-type hypersensitivity is believed to
involve Th1 cells. Since, according to the original Th1/Th2
dichotomy [8] there is an inverse relationship between
Th1 and Th2 responses, we set out to look for substances
that increased Th1 responses and thus, presumably,
would reduce allergy. Moreover, we looked for substances
with broad immunogenic specificity and hence a broad
range of possible therapeutical activity. This criterion fits
substances containing so-called pathogen-associated
molecular patterns, which stimulate innate immunity via
binding to a few different receptors with broad specifici-
ties like Toll-like receptors and dectin-1.
In order to test putative functional Th1-stimulating sub-
stances, a mouse model for systemic bacterial infection
was chosen rather than a tumor model, because of the
more rapid outcome of an anti-bacterial than an anti-
tumor response. We tested different β-glucans, which are
known stimulators of innate immunity with anti-tumor
[9] and anti-infection [10] activities. We found that one β-
1,3-glucan from Sclerotinia sclerotiorum was highly protec-
tive against sepsis in a mouse model for systemic S. pneu-
moniae, although only when given i.p. and not p.o. [11].
However, surprisingly, we detected that s.c. administra-
tion of both this β-glucan and other β-glucans from barley
and baker's yeast, in addition to moulds per se, also
increased specific IgE levels in a mouse model for allergy
[12,13]. This is in agreement with the finding of increased
allergic responses of mold-derived β-1,3-glucan in an air-
way inhalation model in the mouse [14]. Since AbM is
another more recently discovered source of strong innate
stimulatory properties [15,16], with a high content of β-
glucan and anti-tumor properties in the mouse [3], we
tested whether extracts of AbM from different producers
had anti-infection effects in the said mouse model for
pneumococcal sepsis. We found that the current extract,
AndoSan™, containing approximately 80% of AbM and
20% of two other Basidiomycetes mushrooms; Hericium eri-
naceum and Grifola frondosa, was the most effective: It was
the only extract that decreased bacteremia statistically sig-
nificantly and increased the survival rate of the exposed
animals [17]. Moreover, it had more profound anti-infec-
tion effect even when given p.o. via a gastric catheter than
did any of the above β-glucans given i.p..
There are anecdotes about persons who have used AbM
for other purposes than allergy, and who have experi-
enced less allergic symptoms when ingesting the remedy.
To our knowledge the very few papers on AbM or other
Basidiomycetes mushrooms and allergy in English scientific
literature rather report on induction of allergy; cheilitis
and increased delayed-type sensitivity due to AbM
[18,19], hypersensitivity pneumonitis caused by Grifola
frondosa  [20], and allergic contact dermatitis from
Hericeum erinaceum exposure [21]. Based on preliminary
anti-infection and anti-allergy results in our laboratory
with the current extract of mainly AbM (AndoSan™), a
patent application was filed in 2004 [22]. There are other
publications on beneficial effects of the mushrooms in the
patent literature, foremost of Japanese origin: One patent
(A61K 35/84, 05.08.2002) claims that an essence
extracted from mycelium of Basidiomycetes, including Her-
icium erinaceum, can prevent and cure allergic symptoms,
especially atopic dermatitis. Another (WO 02/15917)
claims the use of AbM in treatment of autoimmune and
skin diseases, due to down-regulation of immune func-
tion. Yet another (WO 93/207923) describes the isolation
from Agaricus hortensis of anti-allergic components, espe-
cially for dermatological usage. Extracts of AbM have also
been found to have anti-allergic effect based on inhibition
of basophilic leukocytes (US2003/0104006). Finally,
EP0413053 describes a process for producing an anti-
allergic substance from Basidiomycetes mycelium, includ-
ing that of AbM and Grifola frondosa.
The aim of the present study was to examine whether the
extract that was most effective against systemic pneumo-
coccal infection, also could protect against allergy devel-
opment when given to a mouse model for allergy. For this
purpose the model allergen ovalbumin (OVA) was
injected s.c. and AbM extract as adjuvant was given orally,
and levels of specific IgE and IgG2a antibodies were deter-
mined in serum. In addition, Th1, Th2 and Treg cytokines
were measured in supernatants of cultured spleen cells
from the mice.
Methods
Mice
These were inbred, female, pathogen-free, 6–8 weeks old
NIH/OlaHsd, C57Bl/6 and Balb/c obtained from Gl.
Bomholt gård Ltd (Ry, Denmark) and rested for 1 week
after arrival. They were housed 8 animals per cage, indi-
vidually earmarked, and given water and egg-free feed ad
libitum. Experiments were performed according to law
and regulations for animal experiments in Norway, which
are in agreement with the Helsinki declaration, and they
were approved by the local Animal Board under the min-
ister of Agriculture in Norway.
Reagents
An aqueous extract of mycelium of AbM (82%), contain-
ing additionally Hericium erinaceum (15%) and Grifola
frondosa  (3%) (AndoSan™), grown commercially, was
given by ACE Co., Ltd., Gifu, Japan. It was stored at 4°C
in dark bottles and kept sterile until being instilled intra-
gastrically in the mice. The AbM mixed powder contains
per 100 g the following constituents: moisture 5.8 g, pro-
tein 2.6 g, fat 0.3 g, carbohydrates 89.4 g of which β-glu-
can constitutes 2.8 g, and ash 1.9 g, and its finalClinical and Molecular Allergy 2009, 7:6 http://www.clinicalmolecularallergy.com/content/7/1/6
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concentration was 340 g/l. The amount per liter of the
extract for sodium was 11 mg, phosphorus 254 mg, cal-
cium 35 mg, potassium 483 mg, magnesium 99 mg and
zinc 60 mg. The LPS content of AndoSan™ was found,
using the Limulus  amebocyte lysate test (COAMATIC
Chromo-LAL; Chromogenix, Falmouth, MA, USA) with
detection limit 0.005 EU/ml (1 EU = 0.1 ng/ml), to be a
miniscule concentration of <0.5 pg/ml. The results from
tests for heavy metals were conformable with strict Japa-
nese regulations for health foods. AndoSan™ had been
heat-sterilized (124°C for 1 h) by the producer. Since this
mushroom extract is a commercial product, the method
for its production is a business secret. Ovalbumin (OVA)
(Sigma, St. Louis, MO, USA; cat.no. A7641) and Al(OH)3
were dissolved in PBS of pH 7.3, and each animal was
immunized with 10 μg of OVA and 2 mg of Al(OH)3 in a
total volume of 0.5 ml in the tail base.
Experimental design
Groups of 8 mice were given either 200 μl (according to
their assumed maximal ventricular volume) of the AbM
extract, AndoSan™, or PBS orally via a gastric tube and
injected a day later with OVA +Al(OH)3 s.c. in the tail base
or injected first with OVA +Al(OH)3  s.c. and given
AndoSan™ or PBS p.o. on day 19. With Balb/c mice both
OVA and 20 μl of AndoSan™ or PBS were injected s.c. in
one hind foot pad (for Balb/c mice). Then both groups
were boosted with OVA s.c. on day 20, before sacrifice and
exanguination and removal of the spleen or the foot pad-
draining popliteal lymph nodes (PLN) (for Balb/c mice),
on day 26. Some mice (C57Bl/6) were given additional
AbM or PBS treatment on both day -1 and day 19 before
the OVA boosting. The scheme in Table 1 shows the dif-
ferent set-ups.
Spleen cell cultures
The spleen was removed from each sacrificed mouse and
put in a tube containing Hank's Balanced Salt Solution
(HBSS; Gibco BRL, Paisley, Scotland). A single cell sus-
pension was prepared under sterile condition by placing
the spleen on top of a wire-net in a Petri dish containing
2 ml HBSS. The spleen was punctured by a canula (BD
Microlance™ 3 needle, Becton Dickinson AB, Sweden) and
thereafter a bended glass staff was used to rub the cells
from the spleen capsule through the wire net to make a
single cell suspension. The cell suspensions were washed
in HBSS and resuspended in RPMI (RPMI 1640 culture
medium with 20 mM L-glutamine (Gibco)), containing
10% FCS, 100 U penicillin G and 0.1 mg/ml streptomycin
(PAA Laboratories GmbH). The cell concentration was
measured with a Coulter Counter ZI (Beckman Coulter
Inc., FL, USA). The spleen cells were seeded into a 24-well
culture plates (Costar Inc., NY, USA) to a final concentra-
tion of 5 × 106 cells/ml. OVA or Con A were added to a
final concentration of 1 mg/ml and 6 μg/ml, respectively,
except for unstimulated controls. The cells were cultured
at 37°C and in 5% CO2 for 48 or 72 hours. Thereafter the
plates were centrifuged at 1200 rpm for 5 minutes, and
supernatants were collected and stored at -80C until anal-
ysis.
Assays
Mouse IgE anti-OVA and IgG2a anti-OVA antibodies were
measured in serum, and levels of cytokines IFNγ, IL-2
Table 1: Scheme for experimental design in murine allergy model
Exp # # Mice, strain Treatment before and/or after OVA immunization Harvest
1 16 NIH/OlaHsd AndoSan™ or PBS p.o.* (200 μl) 
↓
serum, spleen
↑
2 16 NIH/OlaHsd AndoSan™/PBS p.o. 
↓
serum, spleen
↑
3 8 C57Bl/6 AndoSan™/PBS p.o. and/or 
↓
AndoSan™/PBS p.o.
↓
serum, spleen
↑
4 8 Balb/c AndoSan™/PBS s.c. in foot pad (20 μl)** 
↓
serum, PLN
↑
Day -1 0 19, 20 26
Immunization ↑
OVA (10 μg) + Al(OH)3 s.c. in tailbase or foot pad + ↑
OVA s.c
↑
Sacrifice
*200 μl of AndoSan™ or PBS was given p.o. via a gastric catheter. ** OVA and Al(OH)3 (2 mg) was dissolved in AndoSan™ or PBS before s.c. 
injection in foot pad.Clinical and Molecular Allergy 2009, 7:6 http://www.clinicalmolecularallergy.com/content/7/1/6
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(Th1 response), IL-4, IL-5 (Th2 response) and IL-10 (Treg
cytokine) in cell culture supernatants by ELISAs. Whereas
the former Ig ELISAs were in-house (sandwich anti-OVA
IgE and simple anti-OVA IgG2a [13]) and the cut-off set to
give negative results in serum from naïve mice, the ones
for the cytokines were from R&D Systems, Minneapolis,
MN, USA. The excised PLN from both injected and non-
injected hind limb were weighed and compared as a
parameter for local inflammation.
Statistics
Sigma Stat (Systat Software, Inc., 1735 Technology Drive
Suite 430 San Jose, CA) statistical and graphics package
was used. When the data were normally distributed para-
metric assays were used, otherwise non-parametric assays.
Student's t-test was used for comparing two groups. One-
way ANOVA was used for single repeated measurements,
and two-ways ANOVA for two experiments with repeated
measurements. P values below 0.05 were considered sta-
tistically significant.
Results
Serum anti-OVA IgE and IgG2a antibodies
We used a mouse model for allergy to examine whether
the medicinal mushroom AbM could protect against this
disease. Experiments were conducted in three mouse
strains with OVA as model allergen and a mushroom
extract, AndoSan™, mainly containing AbM, or PBS con-
trol as adjuvant. In two experiments with NIH/Ola mice,
AbM treatment prior to OVA immunization reduced the
levels of serum anti-OVA IgE antibodies significantly (p =
0.002, two-way ANOVA) compared with similar PBS pre-
OVA treatment (Figure 1) when the animals were sacri-
ficed about 4 weeks after OVA immunization. The levels
of serum anti-OVA IgG2a tended to be higher in the AbM
group (Figure 2), but were not statistically significantly
different from the PBS control. Furthermore, when AbM,
as compared with PBS, was given near 3 weeks after the
allergen immunization of such mice, this treatment also
significantly reduced the levels of anti-OVA IgE (p =
0.048, two-way ANOVA) (Figure 3). In these two experi-
ments the levels of anti-OVA IgG2a in the AbM group, rel-
ative to PBS, seemed to be even higher (Figure 4) than
observed above, but were due to large variation not statis-
tically different from the control.
The next set-up was similar to the ones above, but with
C57Bl/6 mice and included groups that were treated with
AbM or PBS either before or after OVA immunization, or
both before and after the immunization. Figure 5 shows a
tendency towards lower anti-OVA IgE levels in the AbM
compared with PBS treated groups (p = 0.064, one way
ANOVA), albeit the levels of specific IgE of the PBS-OVA-
PBS control (last column in Figure 5) was relatively far
lower than the two other PBS controls. The IgG2a levels
were all-over below the detection limit of the assay and
thus too low for data analysis. In a third set-up with Balb/
c mice, a similar but statistically not significant trend of
AbM-induced lower IgE and higher serum anti-OVA
IgG2a levels was still found when using the foot pad of the
mice for s.c. injection of both OVA and a 1/10 volume of
AndoSan™ (data not shown).
Cytokines in spleen cell cultures and weight of PLN
Occasionally, there were in single experiments reduced
levels (p < 0.05), except increased levels once for IL-2, and
otherwise no significant differences in all the five
cytokines measured; IFNγ, IL-2, IL-4, IL-5 and IL-10, in
spleen cell culture supernatants from animals treated with
AbM relative to PBS control, either before or after OVA
immunization. Table 2 gives cytokine levels as indices of
those for AbM-treated relative to those for PBS treated
controls. For each experiment the highest read-outs above
the detection limit of each assay was used, for set-up with
either OVA or Con A in vitro stimulated cell cultures.
When all indices for all groups of Th2 cytokines (mean
index: 0.87 ± 0.05) were compared with all indices of Th1
cytokines (mean index: 1.07 ± 0.05), Th2 cytokines were
significantly lower (p = 0.026). Hence, there seemed to be
a tendency of reduced Th2 relative to Th1 cytokine levels
in the AbM groups. There were similar weights of the
Levels of OVA-specific IgE measured in mouse serum on day  26 after OVA-pretreatment with AbM Figure 1
Levels of OVA-specific IgE measured in mouse 
serum on day 26 after OVA-pretreatment with AbM. 
Mice were given 200 μl of AndoSan™ extract or PBS intra-
gastrically on day -1 and injected with 10 μg of OVA s.c. in 
the tail base on day 0 and again on day 20, before exsanguin-
ation for serum on day 26. Values are given in arbitrary units 
(AU)/ml and means + 1 s.e.m. for groups of 16 mice (groups 
of 8 per each of 2 experiments). Anti-OVA IgE levels were 
lower in AbM (AndoSan™) than in PBS treated groups (p = 
0.002, two-way ANOVA).
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excised PLN from the AbM and PBS groups, suggesting no
local inflammatory response to the mushroom extract.
Discussion
Our results are strengthened by the similar findings,
observed in two different mouse strains after s.c. injection
of OVA in the tail base, and in a third mouse strain (Balb/
c) after s.c. injection of both mushroom extract and OVA
in the foot pad. In the latter Th2-prone mice the so-called
PLN assay was used, which was originally employed for
toxicological screening of substances that would inflame
the foot pad-draining PLN, but which is also convenient
for examining systemic IgE response in serum to an aller-
gen given with adjuvant [23]. The lacking increase in PLN
weight in mice injected AbM extract relative to PBS in the
foot pad, agrees with the assumed anti-inflammatory anti-
allergic effect of the AbM as seen from the tendency of
generally lowering of Th2 cytokine levels in spleen cell
cultures ex vivo.
Increased specific IgE levels are not equivalent with aller-
gic disease, but a prerequisite for IgE-mediated allergy.
Hence, our findings of decreased anti-OVA IgE levels sec-
ondary to AbM intake in animals that were otherwise sen-
sitized to OVA, strongly indicates a protective effect of
AbM against IgE-mediated allergy. We did not examine
allergy signs in the mice. These would have been similar
to egg allergy, as in food allergy. Possible skin rashes
would have been difficult to assess in the mice, and nude
mice could not have been used because they lack normal
lymphocytes, which are a prerequisite for an allergic
immune response. In possible follow-up studies, the aller-
gen should be given via the natural route; e.g. p.o. if using
ovalbumin, although this would be costly. Instead, a com-
mon food allergen like peanut could have been used, or if
one wished to examine airways allergy in the case of aer-
oallergens, another cheap aeroallergen like birch pollen,
although with novel ELISAs for these antigens. The find-
ing of relatively far lower anti-OVA IgE levels in the
repeated PBS controls in Figure 5, may be due to the stress
invoked by such repeated intragastric procedure. In pre-
liminary experiments, in which repeated pre-OVA treat-
ment of mice with the mushroom extract or PBS was
delivered intragastrically by the highly trained technicians
to increase the dose, all mice looked sick and one animal
died, presumably from stress, which is known to impair
immunity.
Previously, we have used pure β-glucans from yeast and
fungi together with ovalbumin s.c. in the very same PLN
model and, contrary to the present observation, found
increased specific anti-OVA IgE levels in serum [12,13].
Hence, either the administration route is critical, or the
particular β-glucans of the current mushroom extract does
either promote a different outcome than the other β-glu-
cans, or other stronger anti-allergic immunomodulating
substances in the mushroom extract do overcome a possi-
ble general "pro-allergic" effect of β-glucans. If the latter is
true, we assume that the anti-allergy effects of the AbM
extract in vivo is mediated via immunomodulating sub-
stances in the extract that are smaller and more readily
absorbable than β-glucans.
As to possible side effects, there are conflicting reports
regarding the effect of AbM on liver function. Whereas
one report suggests that use of AbM for several weeks may
have induced severe hepatic dysfunction in three cancer
patients [24], another says that AbM extract normalized
liver function in patients with chronic hepatitis B virus
infection [25]. Moreover, our studies on patients with
chronic hepatitis C virus infection [26] and on AbM
intake in healthy volunteers [27], revealed no pathologi-
cal effect whatsoever on hematological parameters includ-
ing those for liver-, pancreatic- and renal function, even
when volumes equivalent by body weight to that given to
the mice, were taken.
The generally observed AbM-induced all-over reduction
in Th2 cytokines IL-4 and IL-5 relative to Th1 cytokines
IFNγ and IL-2 production ex vivo in our present cultures
of spleen cells, agrees with the original Th1/Th2 dichot-
omy [8]. However, this theory has been modified towards
Levels of IgG2a measured in mouse serum on day 26 after  OVA-pretreatment with AbM Figure 2
Levels of IgG2a measured in mouse serum on day 26 
after OVA-pretreatment with AbM. Mice were given 
200 μl of AndoSan™ extract or PBS intragastrically on day -1 
and injected with 10 μg of OVA s.c. in the tail base on day 0 
and again on day 20, before exsanguination for serum on day 
26. Values are given in arbitrary units (AU)/ml and means + 1 
s.e.m. for groups of 16 mice (groups of 8 per each of 2 
experiments).
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suggesting that T regulatory cells are crucial for fine-tuning
both Th1 and Th2 responses by the regulatory cytokines
IL-10 and TGF-β. However, our measurement of sugges-
tive reduced levels of the Treg cytokine IL-10 in the AbM
groups, is difficult to interpret. In contrast, when the
extract was given in vitro to cell cultures there was an
increase in proinflammatory cytokines [15]. This appar-
ent discrepancy must be due to the fact that whereas cells
in vitro are subjected to all substances in the extract
including β-glucans with large m.w., which are abundant
in AbM [3], mainly smaller substances are taken up from
the digestive tract in humans and are active in the blood
in vivo. Although, β-glucans in the intestines could stim-
ulate Peyer's patches in jejunum, we have in fact observed
that the genes in leukocytes predominantly affected by
AbM in vitro and in vivo were quite different [26,28].
Whereas genes related to proinflammatory cytokines were
strongly induced in vitro – presumably by β-glucan, genes
involved in cell signalling and cycling and transcriptional
regulation and thus foremost related to anti-tumor
defence, were upregulated in vivo [26]. Thus, the microar-
ray analyses agree with the assumption that AbM extract
especially promotes a Th1 anti-tumor and anti-infection
response in the body and hence reciprocally inhibits a Th2
response. This is supported by the reported immuno-
modulatory effects of AbM in mice [19].
β-glucans may stimulate macrophages and other cells of
innate immunity after binding to cellular receptors like
CD11b/18, Toll-like receptor and dectin-1 [reviewed in
[17]]. Stimulation by AbM of peripheral blood leukocytes
resulted both in an upregulation of such receptors
[26,28,29], activation of NFKB via TLR2 stimulation [30],
and mediation via them of increased release of proinflam-
matory cytokines [15] and Th1 cytokines IFNγ, IL-12, and
IL-23α [16,28,31]. Although one report of reduced release
of Th2 cytokine IL-4 after AbM stimulation in vitro also
found reduced IL-2 and IFNγ levels [32], IL-12- and IFNγ-
mediated NK cell activation by AbM p.o. has been docu-
mented in mice [16]. Even though the present AbM extract
should occasionally give reduced IFNγ levels, the
increased expression of the IFN receptor gene after AbM
extract intake in humans [26], may overcome a reduction
in the concentration of the ligand and result in an
increased Th1 response. When measuring different
cytokines in serum from humans after 12 days intake of
the current AndoSan™ extract mainly containing AbM,
there was a significant reduction in both pro-inflamma-
tory, Th1 and Th2 cytokines [31]. This indicates a general
anti-inflammatory effect of AndoSan™ in vivo, which
agrees with its current anti-allergic effect.
Levels of OVA-specific IgE measured in mouse serum on day 26 after OVA-post treatment with AbM Figure 3
Levels of OVA-specific IgE measured in mouse serum on day 26 after OVA-post treatment with AbM. Mice 
were injected with 10 μg of OVA on day 0 and given 200 μl of AndoSan™ extract or PBS intragastrically on day 19, before 
OVA booster on day 20 and sacrifice on day 26. Values are given in AU/ml and means + 1 s.e.m. for groups of 16 mice (groups 
of 8 per each of 2 experiments). Anti-OVA IgE levels were lower in AbM (AndoSan™) than PBS treated groups (p = 0.048, 
two-way ANOVA).
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For intragastric delivery of AbM extract a volume of 200 μl
was chosen because this is, according to our veterinary,
the maximal ventricular volume in a 5–6 weeks old
mouse. In an initial experiment, we tried to give the AbM
extract repeatedly on subsequent days via a gastric catheter
in order to possibly inhibit the specific IgE response com-
pletely. However, this procedure was dropped because it
was too stressful for the mice even in hands of our well-
trained technicians. The unexpected result in the last two
columns of Figure 5 may in fact reflect this concern. Also,
we did not use a higher concentration of this extract than
what was sold on the health food market. If translated to
human intake, the equivalent of 200 μl to a 25 g mouse
would be 560 ml to a 70 kg individual. In fact, a daily low
intake in healthy volunteers of 60 ml AndoSan™ for 12
days gave a significant 50% reduction in levels of the
allergy-promoting cytokine IL-4 in blood and left the
other allergy-related cytokines IL-5, IL-7 and IL-13 at neg-
ligible levels [27]. Addition of AbM extract to drink water
for the mice in our set-up would have been more natural,
but the intake of AbM is impossible to monitor as accu-
rately as with intragastric delivery. In the current allergy
model we did not test other extracts of AbM from other
manufacturers that did not have a significant effect against
pneumococcal infection in mice [17]. Therefore, the ques-
tion is not fully answered as to whether there is an abso-
lute link between the anti-bacterial infection and anti-
allergy effect of a substance or an extract like AndoSan™.
Moreover, even though we have seen that Agaricus bM is
the main TLR2 stimulating mushroom of AndoSan™ [30],
it is likely that the former anti-bacterial and current anti-
allergic effect of this mixed mushroom product may be
partly due to possible synergistic effects of the other
mushrooms, Hericium erinaceum and Grifola frondosa, and
components thereof contained in the extract. The mouse
model of allergic airways disease should be used in a fol-
low-up study with OVA and the mushroom extract in
order to confirm that also allergic symptoms like develop-
ment of airways hyper responsiveness are reduced by
AndoSan™ intake. Whether the AbM extract is effective
against allergy in the human setting must be tested in a
clinical trial, e.g. in persons with aeroallergy during the
pollen season taking 60 ml a day for a few weeks.
Conclusion
From our results with mice we conclude that a mushroom
extract, mainly containing AbM, may prevent the develop-
ment of IgE-mediated allergy when given before allergen
immunization. Even more interesting, the extract seemed
to have a therapeutic effect when given together with or as
Levels of IgG2a measured in mouse serum on day 26 after OVA-post treatment with AbM Figure 4
Levels of IgG2a measured in mouse serum on day 26 after OVA-post treatment with AbM. Mice were injected 
with 10 μg of OVA on day 0 and given 200 μl of AndoSan™ extract or PBS intragastrically on day 19, before OVA booster on 
day 20 and sacrifice on day 26. Values are given in AU/ml and means + 1 s.e.m. for groups of 16 mice (groups of 8 per each of 
2 experiments).
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late as 3 weeks after the allergen immunization. Three
weeks in the mouse equals several months in a human,
suggesting that also established allergy in patients can be
reverted.
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